Skip to main content
. 2021 Nov 2;12:734671. doi: 10.3389/fphar.2021.734671

TABLE 4.

Comparison of cardiotoxicity between crassicauline A and its converted products.

Compound Dose (mg/kg) VPB incubation period (s) VT incidence (%)
Crassicauline A 0.10 182.8 ± 84.58 100
Compound 1 0.10 0
Compound 2 0.10 0
Compound 4 0.10 0

“—”means that no arrhythmia occurred within 30 min after the administration of experimental compound. Data are expressed as mean ± S.D. (n = 10).